Literature DB >> 22531377

Transient expression of Xpn, an XLMR protein related to neurite extension, during brain development and participation in neurite outgrowth.

T Ishikawa1, S Miyata, Y Koyama, K Yoshikawa, T Hattori, N Kumamoto, K Shingaki, T Katayama, M Tohyama.   

Abstract

KIAA2022 has been implicated as a gene responsible for expressing X-linked mental retardation (XLMR) proteins in humans. However, the functional role of KIAA2022 in the human brain remains unclear. Here, we revealed that depletion of Kiaa2022 inhibits neurite outgrowth of PC12 cells, indicating that the gene participates in neurite extension. Thus, we termed Kiaa2022 as an XLMR protein related to neurite extension (Xpn). Using the mouse brain as a model and ontogenetic analysis of Xpn by real-time PCR, we clearly demonstrated that Xpn is expressed transiently during the late embryonic and perinatal stages. In situ hybridization histochemistry further revealed that Xpn-expressing neurons could be categorized ontogenetically into three types. The first type showed transient expression of Xpn during development. The second type maximally expressed Xpn during the late embryonic or perinatal stage. Thereafter, Xpn expression in this type of neuron decreased gradually throughout development. Nevertheless, a significant level of Xpn expression was detected even into adulthood. The third type of neurons initiated expression of Xpn during the embryonic stage, and continued to express the gene throughout the remaining developmental stages. Subsequent immunohistochemical analysis revealed that Xpn was localized to the nucleus and cytoplasm throughout brain development. Our findings indicate that Xpn may participate in neural circuit formation during developmental stages via nuclear and cytoplasmic Xpn. Moreover, disturbances of this neuronal circuit formation may play a role in the pathogenesis of mental retardation.
Copyright © 2012 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22531377     DOI: 10.1016/j.neuroscience.2012.04.030

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  13 in total

1.  NEXMIF/KIDLIA Knock-out Mouse Demonstrates Autism-Like Behaviors, Memory Deficits, and Impairments in Synapse Formation and Function.

Authors:  James Gilbert; Margaret O'Connor; Sebastian Templet; Mahsa Moghaddam; Anaïs Di Via Ioschpe; Amanda Sinclair; Ling-Qiang Zhu; Weifeng Xu; Heng-Ye Man
Journal:  J Neurosci       Date:  2019-11-08       Impact factor: 6.167

2.  Clonazepam as an Effective Treatment for Epilepsy in a Female Patient with NEXMIF Mutation: Case Report.

Authors:  Masashi Ogasawara; Eiji Nakagawa; Eri Takeshita; Kohei Hamanaka; Satoko Miyatake; Naomichi Matsumoto; Masayuki Sasaki
Journal:  Mol Syndromol       Date:  2020-09-01

3.  Loss of function of KIAA2022 causes mild to severe intellectual disability with an autism spectrum disorder and impairs neurite outgrowth.

Authors:  Lionel Van Maldergem; Qingming Hou; Vera M Kalscheuer; Marlène Rio; Martine Doco-Fenzy; Ana Medeira; Arjan P M de Brouwer; Christelle Cabrol; Stefan A Haas; Pierre Cacciagli; Sébastien Moutton; Emilie Landais; Jacques Motte; Laurence Colleaux; Céline Bonnet; Laurent Villard; Juliette Dupont; Heng-Ye Man
Journal:  Hum Mol Genet       Date:  2013-04-24       Impact factor: 6.150

4.  Rare complete knockouts in humans: population distribution and significant role in autism spectrum disorders.

Authors:  Elaine T Lim; Soumya Raychaudhuri; Stephan J Sanders; Christine Stevens; Aniko Sabo; Daniel G MacArthur; Benjamin M Neale; Andrew Kirby; Douglas M Ruderfer; Menachem Fromer; Monkol Lek; Li Liu; Jason Flannick; Stephan Ripke; Uma Nagaswamy; Donna Muzny; Jeffrey G Reid; Alicia Hawes; Irene Newsham; Yuanqing Wu; Lora Lewis; Huyen Dinh; Shannon Gross; Li-San Wang; Chiao-Feng Lin; Otto Valladares; Stacey B Gabriel; Mark dePristo; David M Altshuler; Shaun M Purcell; Matthew W State; Eric Boerwinkle; Joseph D Buxbaum; Edwin H Cook; Richard A Gibbs; Gerard D Schellenberg; James S Sutcliffe; Bernie Devlin; Kathryn Roeder; Mark J Daly
Journal:  Neuron       Date:  2013-01-23       Impact factor: 17.173

5.  Novel NEXMIF pathogenic variant in a boy with severe autistic features, intellectual disability, and epilepsy, and his mildly affected mother.

Authors:  Nelle Lambert; Corinne Dauve; Emmanuelle Ranza; Periklis Makrythanasis; Federico Santoni; Frédérique Sloan-Béna; Stefania Gimelli; Jean-Louis Blouin; Michel Guipponi; Armand Bottani; Stylianos E Antonarakis; Markus M Kosel; Joel Fluss; Ariane Paoloni-Giacobino
Journal:  J Hum Genet       Date:  2018-05-01       Impact factor: 3.172

6.  The Kampo Medicine Yokukansan Decreases MicroRNA-18 Expression and Recovers Glucocorticoid Receptors Protein Expression in the Hypothalamus of Stressed Mice.

Authors:  Shoko Shimizu; Takashi Tanaka; Takashi Takeda; Masaya Tohyama; Shingo Miyata
Journal:  Biomed Res Int       Date:  2015-05-14       Impact factor: 3.411

7.  The X-Linked Autism Protein KIAA2022/KIDLIA Regulates Neurite Outgrowth via N-Cadherin and δ-Catenin Signaling.

Authors:  James Gilbert; Heng-Ye Man
Journal:  eNeuro       Date:  2016-10-28

Review 8.  Fundamental Elements in Autism: From Neurogenesis and Neurite Growth to Synaptic Plasticity.

Authors:  James Gilbert; Heng-Ye Man
Journal:  Front Cell Neurosci       Date:  2017-11-20       Impact factor: 5.505

Review 9.  Candidate Genes for Eyelid Myoclonia with Absences, Review of the Literature.

Authors:  Sonia Mayo; Irene Gómez-Manjón; Fco Javier Fernández-Martínez; Ana Camacho; Francisco Martínez; Julián Benito-León
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

10.  Association between chronic stress-induced structural abnormalities in Ranvier nodes and reduced oligodendrocyte activity in major depression.

Authors:  Shingo Miyata; Manabu Taniguchi; Yoshihisa Koyama; Shoko Shimizu; Takashi Tanaka; Fumihiko Yasuno; Akihide Yamamoto; Hidehiro Iida; Takashi Kudo; Taiichi Katayama; Masaya Tohyama
Journal:  Sci Rep       Date:  2016-03-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.